Raising Expectations
Building best-in-class therapeutics to reduce the burden of neurodegenerative diseases because patients and caregivers deserve better.
Overcoming Barriers
Delivering safe, efficacious drugs to the central nervous system (CNS) remains one of the greatest challenges in medicine. This is driven by the blood-brain barrier (BBB), which restricts the entry of large molecules into the CNS, preventing many potential therapeutics from reaching their intended targets.
In partnership with Paragon Therapeutics, Korsana has developed Therapeutic Targeting (THETA™), a novel BBB-penetrant shuttle platform designed to enhance CNS exposure of investigational therapies and overcome limitations of earlier shuttle technologies.
Using THETA, Korsana is advancing precision-engineered therapeutics designed to reduce the burden of some of medicine’s biggest challenges, starting with Alzheimer’s disease.
Learn more about the burden and difficulties of treating Alzheimer’s disease, and our potential best-in-class therapeutic approach.
Latest News
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases
Lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease